Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Marinus Pharmaceuticals (NASDAQ: MRNS) announced its participation in key investor conferences in November and December.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/15/2021 - 07:30 AM EST

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that members of its leadership team will present at the following investor conferences in November and December.

12th Annual Jefferies London Healthcare Conference

Date and Time: Available on demand starting Thursday, November 18, 3:00 a.m. ET through Friday, November 19, 12:00 p.m. ET
Speakers: Scott Braunstein, M.D., Chief Executive Officer and Steven Pfanstiel, Chief Financial Officer
Webcast Link: https://wsw.com/webcast/jeff201/mrns/1865664

Marinus Pharmaceuticals Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting

Date and Time: Monday, December 6, 1:00–2:30 p.m. ET
Webcast Link: https://wsw.com/webcast/cc/mrns4/1448568

Jefferies Denver Healthcare Summit

Date and Time: Thursday, December 16
One-on-one meetings with Marinus leadership open only to Jefferies conference participants

About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a positive allosteric modulator of GABA_A receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year, is planning to conduct a Phase 3 trial in tuberous sclerosis complex, and a Phase 3 trial in refractory status epilepticus is ongoing. For more information visit www.marinuspharma.com.